
Type 2 Diabetes - Pipeline Insight, 2025
Description
DelveInsight’s, “Type 2 Diabetes - Pipeline Insight, 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Type 2 Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Type 2 Diabetes: Overview
Type 2 diabetes mellitus (T2DM) is a chronic condition that affects the way the body processes blood sugar (glucose). In T2DM, the response to insulin is diminished, and this is defined as insulin resistance. During this state, insulin is ineffective and is initially countered by an increase in insulin production to maintain glucose homeostasis, but over time, insulin production decreases, resulting in T2DM. T2DM is most commonly seen in persons older than 45 years. Still, it is increasingly seen in children, adolescents, and younger adults due to rising levels of obesity, physical inactivity, and energy-dense diets.
T2DM is an insulin-resistance condition with associated beta-cell dysfunction. Initially, there is a compensatory increase in insulin secretion, which maintains glucose levels in the normal range. As the disease progresses, beta cells change, and insulin secretion is unable to maintain glucose homeostasis, producing hyperglycemia. Most of the patients with T2DM are obese or have a higher body fat percentage, distributed predominantly in the abdominal region. This adipose tissue itself promotes insulin resistance through various inflammatory mechanisms, including increased FFA release and adipokine dysregulation. Lack of physical activity, prior GDM in those with hypertension or dyslipidemia also increases the risk of developing T2DM. Evolving data suggest a role for adipokine dysregulation, inflammation, abnormal incretin biology with decreased incretins such as glucagon-like peptide-1 (GLP-I) or incretin resistance, hyperglucagonemia, increased renal glucose reabsorption, and abnormalities in gut microbiota.
The diagnostic procedure to confirm type 2 diabetes fasting plasma glucose (FPG) test, A1C test, random plasma glucose (RPG), and oral glucose tolerance test are carried out. For A1C, the normal range should be below 5.7%, fasting plasma glucose should be 99 mg/dL or below, and oral glucose tolerance should be 139 mg/dL or below. Diabetes can be treated and its consequences avoided or delayed with diet, physical activity, medication and regular screening and treatment for complications. Medications include metformin, meglitinides and sulfonylureas, DPP-4 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, SGLT2 inhibitors, bile acid sequestrants etc. In September 2019, the US Food and Drug Administration approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise.
""Type 2 Diabetes- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type 2 Diabetes pipeline landscape is provided which includes the disease overview and Type 2 Diabetes treatment guidelines. The assessment part of the report embraces, in depth Type 2 Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 2 Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Type 2 Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type 2 Diabetes Emerging Drugs
Further product details are provided in the report……..
Type 2 Diabetes: Therapeutic Assessment
This segment of the report provides insights about the different Type 2 Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
Type 2 Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 2 Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 2 Diabetes drugs.
Type 2 Diabetes Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 4-5 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Type 2 Diabetes: Overview
Type 2 diabetes mellitus (T2DM) is a chronic condition that affects the way the body processes blood sugar (glucose). In T2DM, the response to insulin is diminished, and this is defined as insulin resistance. During this state, insulin is ineffective and is initially countered by an increase in insulin production to maintain glucose homeostasis, but over time, insulin production decreases, resulting in T2DM. T2DM is most commonly seen in persons older than 45 years. Still, it is increasingly seen in children, adolescents, and younger adults due to rising levels of obesity, physical inactivity, and energy-dense diets.
T2DM is an insulin-resistance condition with associated beta-cell dysfunction. Initially, there is a compensatory increase in insulin secretion, which maintains glucose levels in the normal range. As the disease progresses, beta cells change, and insulin secretion is unable to maintain glucose homeostasis, producing hyperglycemia. Most of the patients with T2DM are obese or have a higher body fat percentage, distributed predominantly in the abdominal region. This adipose tissue itself promotes insulin resistance through various inflammatory mechanisms, including increased FFA release and adipokine dysregulation. Lack of physical activity, prior GDM in those with hypertension or dyslipidemia also increases the risk of developing T2DM. Evolving data suggest a role for adipokine dysregulation, inflammation, abnormal incretin biology with decreased incretins such as glucagon-like peptide-1 (GLP-I) or incretin resistance, hyperglucagonemia, increased renal glucose reabsorption, and abnormalities in gut microbiota.
The diagnostic procedure to confirm type 2 diabetes fasting plasma glucose (FPG) test, A1C test, random plasma glucose (RPG), and oral glucose tolerance test are carried out. For A1C, the normal range should be below 5.7%, fasting plasma glucose should be 99 mg/dL or below, and oral glucose tolerance should be 139 mg/dL or below. Diabetes can be treated and its consequences avoided or delayed with diet, physical activity, medication and regular screening and treatment for complications. Medications include metformin, meglitinides and sulfonylureas, DPP-4 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, SGLT2 inhibitors, bile acid sequestrants etc. In September 2019, the US Food and Drug Administration approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise.
""Type 2 Diabetes- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type 2 Diabetes pipeline landscape is provided which includes the disease overview and Type 2 Diabetes treatment guidelines. The assessment part of the report embraces, in depth Type 2 Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 2 Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Type 2 Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve Type 2 Diabetes.
This segment of the Type 2 Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type 2 Diabetes Emerging Drugs
- LY-3209590: Eli Lilly and Company
- THDB0206: Tonghua Dongbao Pharmaceutical
- HU6: Rivus Pharmaceuticals
- AZD5004: AstraZeneca
- XW014: Sciwind Biosciences
- KN056: Suzhou Alphamab Co., Ltd.
Further product details are provided in the report……..
Type 2 Diabetes: Therapeutic Assessment
This segment of the report provides insights about the different Type 2 Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Type 2 Diabetes
- There are approx. 75+ key companies which are developing the therapies for Type 2 Diabetes. The companies which have their Type 2 Diabetes drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company and Tonghua Dongbao Pharmaceutical.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Type 2 Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 2 Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 2 Diabetes drugs.
Type 2 Diabetes Report Insights
- Type 2 Diabetes Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Type 2 Diabetes drugs?
- How many Type 2 Diabetes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type 2 Diabetes?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type 2 Diabetes therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Type 2 Diabetes and their status?
- What are the key designations that have been granted to the emerging drugs?
- Tonghua Dongbao Pharmaceutical
- Eli Lilly and Company
- Rivus Pharmaceuticals
- Celon Pharma
- Sciwind Biosciences
- AstraZeneca
- Suzhou Alphamab Co., Ltd.
- Neurodon
- Abarceo Pharma
- Chong Kun Dang Pharmaceutical
- THDB0206
- LY-3209590
- HU6
- CPL207280
- XW014
- AZD5004
- KN056
- RGT001-075
- NRDN-101
- Research programme: type 2 diabetes mellitus therapeutics
- CKD-383
Please Note: It will take 4-5 business days to complete the report upon order confirmation.
Table of Contents
240 Pages
- Introduction
- Executive Summary
- Type 2 Diabetes: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Type 2 Diabetes– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- LY-3209590: Eli Lilly and Company
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- HU6: Rivus Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- KN056: Suzhou Alphamab Co., Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Type 2 Diabetes Key Companies
- Type 2 Diabetes Key Products
- Type 2 Diabetes- Unmet Needs
- Type 2 Diabetes- Market Drivers and Barriers
- Type 2 Diabetes- Future Perspectives and Conclusion
- Type 2 Diabetes Analyst Views
- Type 2 Diabetes Key Companies
- Appendix
- *The Table of Contents is not exhaustive; will be provided in the final report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.